News &amp; Updates

Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.

Pembrolizumab plus lenvatinib effective against nonclear cell RCC

29 Feb 2024

Cilostazol, ticagrelor more cost-effective than standard therapy for acute ischaemic stroke

Use of CYP2C19 genotype-guided antiplatelet therapy with cilostazol or ticagrelor as a substitute to clopidogrel is more cost-effective than conventional antiplatelet therapy for patients with acute minor ischaemic stroke and high-risk transient ischaemic attack, suggests a China study.

Cilostazol, ticagrelor more cost-effective than standard therapy for acute ischaemic stroke

29 Feb 2024

Early-onset oculomotor neuropathy ups dementia risk

Adults who develop ocular motor cranial neuropathy (OMCN), particularly at a younger age, are at greater risk of having dementia, reveals a study.

Early-onset oculomotor neuropathy ups dementia risk

29 Feb 2024

TKI-ICI combo offers hope for prostate cancer patients with poor prognosis

A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.

TKI-ICI combo offers hope for prostate cancer patients with poor prognosis

29 Feb 2024

Investigational drug scores big in mild-to-moderate AD, plaque psoriasis

The topical phosphodiesterase 4 inhibitor PF-07038124 is safe and helps lower disease activity in patients with mild-to-moderate atopic dermatitis (AD) and plaque psoriasis, according to the results of a phase IIa study.

Investigational drug scores big in mild-to-moderate AD, plaque psoriasis

HKUMed’s new leadership team poised to reach new heights

The new leadership team of LKS Faculty of Medicine of the University of Hong Kong (HKUMed), led by Dean of Medicine, Professor Chak-Sing Lau, is poised to reach new heights in medical education and research through extensive development plans.

HKUMed’s new leadership team poised to reach new heights

Greater weight loss associated with higher likelihood of T2DM remission

A population-based observational cohort study of >37,000 people in Hong Kong shows that greater weight loss within the first year of type 2 diabetes mellitus (T2DM) diagnosis is associated with an increased likelihood of achieving and sustaining diabetes remission.

Greater weight loss associated with higher likelihood of T2DM remission

People with vision impairment prone to psychosocial problems

Vision impairment appears to contribute to several psychosocial outcomes, including depression, anxiety, and social isolation, according to a study.

People with vision impairment prone to psychosocial problems

Experimental COVID-19 drug shows promising antiviral efficacy in Asians

28 Feb 2024 by

The oral SARS-CoV-2 3C-like protease inhibitor ensitrelvir fumaric acid helps speed up recovery time for COVID-19 symptoms in patients with mild-to-moderate infection, according to the phase III data from the phase II/III SCORPIO-SR study conducted in Asia.

Experimental COVID-19 drug shows promising antiviral efficacy in Asians

Loading, maintenance doses of teicoplanin need adjustments in MRSA patients

A recent study recommends adjusting both loading dosing and maintenance dosing regimens of teicoplanin based on the renal function and serum albumin concentration of patients with methicillin-resistant staphylococcus aureus (MRSA) infection.

Loading, maintenance doses of teicoplanin need adjustments in MRSA patients